Edwards Lifesciences Corp (EW)

Gross profit margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Gross profit (ttm)	US$ in thousands	4,625,000	4,538,200	4,472,900	4,390,200	4,302,000	4,231,800	4,165,100	4,102,300	3,983,600	3,858,800	3,720,200	3,365,300	3,305,700	3,298,200	3,239,900	3,336,000	3,233,600	3,088,700	2,968,800	2,883,400
Revenue (ttm)	US$ in thousands	5,997,700	5,823,000	5,652,900	5,488,400	5,362,000	5,360,300	5,343,800	5,344,000	5,219,100	5,093,000	4,925,300	4,477,100	4,393,400	4,375,800	4,330,900	4,493,400	4,355,200	4,158,800	3,968,100	3,822,500
Gross profit margin		77.11%	77.94%	79.13%	79.99%	80.23%	78.95%	77.94%	76.76%	76.33%	75.77%	75.53%	75.17%	75.24%	75.37%	74.81%	74.24%	74.25%	74.27%	74.82%	75.43%

December 31, 2023 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $4,625,000K ÷ $5,997,700K
= 77.11%

The gross profit margin of Edwards Lifesciences Corp has displayed relatively stable and consistently high levels over the past eight quarters. It ranged from a high of 79.93% in Q4 2022 to a low of 76.58% in Q1 2022. The overall trend shows a slight fluctuation in the margins, with the most recent quarter, Q4 2023, reporting a margin of 77.02%.

The consistently high gross profit margins indicate the company's ability to effectively manage its production costs and generate profits from its core operations. This is a positive signal for investors and stakeholders, as it reflects the company's efficiency in generating revenue after accounting for the cost of goods sold. However, it is important for the company to monitor any downward trends in the gross profit margin as it could indicate potential challenges in cost control or pricing strategies.